RecruitingPhase 4NCT05758532

Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in Children

Harnessing the Beneficial Non-specific Effects of Measles-mumps-rubella Vaccine in Children on Infection With Unrelated Pathogens and Allergic Diseases - a Single-centre Phase IV RCT With a Factorial Design

Sponsor

Laure Pittet, MD-PhD

Enrollment

500 participants

Start Date

Mar 17, 2023

Study Type

INTERVENTIONAL

Conditions

Infections Allergy Eczema Respiratory Tract Infections

Summary

The goal of this clinical trial is to evaluate the off-target/non-specific effects of the measles-mumps-rubella (MMR) vaccine in children.

Eligibility

Min Age: 6 MonthsMax Age: 6 Months

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Measles-Mumps-Rubella vaccine (MMR) for people with allergy, eczema, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 6 Months to 6 Months.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALMeasles-Mumps-Rubella vaccine (MMR)

0.5 ml of MMR vaccine injected intramuscularly in the deltoid region or in the anterolateral area of the thigh

Locations(1)

University Hospitals of Geneva

Geneva, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05758532

Related Trials

Effects of Treatments on Atopic Dermatitis

NCT016316171 location

Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)

NCT000061501 location